Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,165.08
(
0.80%
)
US TECH 100
26,538.40
(
1.85%
)
Dow Jones
49,247.66
(
-0.13%
)
Brent Oil
100.66
(
0.00%
)
Bitcoin
77,794.71
(
0.22%
)
News Focus
News Focus
Post# of 822890
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

SkyLimit2022

Send PM Follow Ignore
Followers 67
Posts 2909
Boards Moderated 0
Alias Born 04/22/2022

SkyLimit2022

Re: meirluc post# 547626

Sunday, 12/11/2022 10:59:23 PM

Sunday, December 11, 2022 10:59:23 PM

Post# of 822890
That’s an interesting question regarding primary tumor as opposed to the recurrent. I am certainly not qualified to explain it because the treatment protocols are different for the PD1 study and the P3 obviously did not include the same agents.

Anyone can see that there is clearly significant evidence of efficacy for all three groups.

However, the efficacy for “Adi ATL-DC + PD-1 mAb” is amazing and it will be a fascinating data set to analyze when it’s more complete!
Bullish
Bullish

Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NWBO News
More NWBO News